Glybera

Type: Product
Name: Glybera
First reported Apr 16 2014 - Updated Apr 16 2014 - 2 reports

3 Stocks To Profit From The Gene Therapy Revolution

Britain's Queen Victoria left an unfortunate legacy: Her descendants, spread across numerous European royal families, all inherited a genetic mutation that causes hemophilia. In fact, one out of every 5,000 to 10,000 males in the world is born with the ... [Published StreetAuthority - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

uniQure appoints new COO

uniQure N.V., a Netherlands-based pharmaceutical company, has appointed Eric Goossens as its new COO with a primary responsibility for manufacturing and project management. Mr Goossens has a 15-year track record of management and leadership in technology-based ... [Published Individual.com - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 1 reports

FDA Grants Breakthrough Status to Gene Therapy for First Time

| Celladon today became the first company to receive breakthrough status for a gene therapy treatment in development. The treatment, MYDICAR, is intended to reduce the risk of heart failure in patients with a deficiency of the enzyme SERCA2a.The FDA made ... [Published Bio-IT World - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 2 reports

uniQure Announces Changes in Management Team

(GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr. Goossens has ... [Published Virtual Strategy Magazine - Apr 09 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

[tt] [GRG] NewAbs: Genome Editing to Cure AIDS

To Members and Friends of the Los Angeles Gerontology Research Group:         Genome editing to cure disease... -- Steve Coles " Can Genome Editing Cure AIDS? " by Hank Greely, Center for Law and Biosciences at Stanford Law School and by ... [Published TranshumanTech - Mar 27 2014]
Entities: Genome, HIV/AIDS, Mutation
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Gene Expression Analysis Market (Gene Profiling, Bioinformatics, Data Analysis Software) worth $4.3 Billion by 2018 - New Report by MarketsandMarkets

This report broadly categorizes the global gene expression analysis market into three segments, namely, instrumentation, consumables, and services. According to the new market research report, “Gene Expression Analysis Market by Technology (DNA Microarray, ... [Published PRWeb - Mar 27 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

UniQure to Present at Future Leaders in Biotech Conference

(GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 21st Annual Future Leaders in the Biotech Industry Conference March 28, 2014, to be held at the ... [Published BusinessWeek - Mar 21 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

EMA looks at flexible drug licensing

The European Medicines Agency (EMA) has made good on its promise to look at adaptive licensing - staggered approval of new therapies to balance access with safety evidence - with the launch of a new pilot.The EMA is looking for volunteer companies to ... [Published PMLive - Mar 20 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 4 reports

uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients

(GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading international pharmaceutical company, today announced initial analysis of retrospectively collected individual patient ... [Published BioSpace - Mar 17 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Six-year follow-up data from Glybera treated patients

Netherlands-based human gene company uniQure (Nasdaq: QURE) and privately-held Italian drugmaker Chiesi Farmaceutici have announced initial analysis of retrospectively collected individual patient data from lipoprotein lipase deficiency (LPLD) patients ... [Published Pharma Letter - Mar 17 2014]
First reported Feb 07 2014 - Updated Feb 07 2014 - 1 reports

These Days, You Can't Spell Financings Of The Fortnight Without "I-P-O"

It turns out a lot of the words that contain the letters "IPO" are biomedical words: Pluripotent. Liposomal. Adiposis. Gallipot . And it turns out a lot of biomedical companies have IPO in them, too. Since we last met 14 days ago , dear reader, ... [Published The IN VIVO Blog - Feb 07 2014]
Entities: IPOs, Insider, Glybera, VCs
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Dutch gene therapy pioneer raises $82 mln in U.S. IPO-Reuters

(Reuters) – A small Dutch company behind the Western world’s first approved gene therapy priced its shares above the expected range in a U.S. stock offering on Wednesday, showing the current investor appetite for biotechnology. Amsterdam-based uniQure ... [Published PE Hub Blog - Feb 06 2014]

Quotes

Yet there is a lot to like about this business model: Analysts at Leerink Swan say UniQure "currently appears maturely positioned with the multitude of layers key to successful gene therapy" citing its deep pipeline of drugs in clinical trials, hefty amount of intellectual property, and looming catalysts in the form of trial progress updates...
...uniQure has initiated the search for a new CFO. Mr Aldag commented: "Piers has been an integral part of uniQure's development for the past 5 years. His support and expertise have been invaluable to the company, ultimately resulting in this year's successful IPO. We wish him success in his new endeavors."
...Regulators have traditionally been wary of the technology after a number of dramatic clinical trial fatalities in the late "90s and early 2000s. However, safety has continually improved in recent years and the freeze on gene therapy may be nearing its end, as a number of companies like Amgen and Bluebird Bio have brought treatments into late-stage clinical trials. MYDICAR, like most gene therapies now in active development, uses a modified adeno-associated virus as a delivery vehicle, inserting a healthy copy of the SERCA2a gene into patients" cardiac muscle cells
...has voiced its support for the pilot, with the BioIndustry Association in the UK saying it would encourage its members to join the pilot having "campaigned for the introduction of adaptive licensing for a number of years”."

More Content

All (20) | News (15) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
3 Stocks To Profit From The Gene Therapy Revolu... [Published StreetAuthority - Apr 16 2014]
Amid The Biotech Sell-Off, Target This Sector [Published Nasdaq - Apr 16 2014]
uniQure appoints new COO [Published Individual.com - Apr 14 2014]
FDA Grants Breakthrough Status to Gene Therapy ... [Published Bio-IT World - Apr 10 2014]
uniQure Announces Changes in Management Team [Published Virtual Strategy Magazine - Apr 09 2014]
UniQure Announces Changes in Management Team [Published BusinessWeek - Apr 09 2014]
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
Gene Expression Analysis Market (Gene Profiling... [Published PRWeb - Mar 27 2014]
UniQure to Present at Future Leaders in Biotech... [Published BusinessWeek - Mar 21 2014]
EMA looks at flexible drug licensing [Published PMLive - Mar 20 2014]
uniQure And Chiesi Farmaceutici SpA Announce Si... [Published BioSpace - Mar 17 2014]
Six-year follow-up data from Glybera treated pa... [Published Pharma Letter - Mar 17 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published Noodls - Mar 17 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published 4 Traders - Mar 17 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published Benzinga.com - Mar 17 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
Dutch gene therapy pioneer raises $82 mln in U.... [Published PE Hub Blog - Feb 06 2014]
Europe: Early Communications with Regulators is... [Published Pharmaceutical Executive - Jan 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Genome editing to cure disease... -- Steve Coles " Can Genome Editing Cure AIDS? " by Hank Greely, Center for Law and Biosciences at Stanford Law School and by ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
It turns out a lot of the words that contain the letters "IPO" are biomedical words: Pluripotent. Liposomal. Adiposis. Gallipot . And it turns out a lot of biomedical companies have IPO in them, too. Since we last met 14 days ago , dear reader, ...
Dutch gene therapy pioneer raises $82 mln in U.... [Published PE Hub Blog - Feb 06 2014]
(Reuters) – A small Dutch company behind the Western world’s first approved gene therapy priced its shares above the expected range in a U.S. stock offering on Wednesday, showing the current investor appetite for biotechnology. Amsterdam-based uniQure ...
1

Press Releases

sort by: Date | Relevance
uniQure and Chiesi Announce Six Year Follow-up ... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.